Methods of treating OX40 mediated recall immune responses and agents useful for identifying same
View Patent ↗T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and persistence of Th2 memory when antigen is re-encountered. In an animal model of allergic asthma, inhibiting OX40/OX40L signaling during the secondary response to inhaled antigen suppressed lung inflammation. Inhibiting OX40 at the time of memory cell reactivation reduced the longevity of memory with further inflammation prevented upon tertiary encounter with antigen.
1. A method of reducing or inhibiting a recall immune response, wherein the recall response is associated with or causes asthma comprising administering an amount of an antibody or fragment thereof that binds to OX40 and reduces or inhibits OX40 signaling, expression or activity sufficient to reduce or inhibit a recall immune response.
2. The method of claim 1 , wherein said immune response is mediated at least in part by OX40 or OX40 ligand (OX40L).
3. The method of claim 1 , wherein said recall response is a secondary, tertiary or subsequent immune response to an antigen.
4. The method of claim 1 , wherein the recall response occurs in lung, or respiratory tract.
5. The method of claim 1 , wherein the agent is administered to a mammalian subject.
6. The method of claim 5 , wherein the mammalian subject is a human.
7. The method of claim 5 , wherein the mammalian subject has one or more symptoms of asthma.
8. A method of alleviating or ameliorating a symptom associated with a secondary or subsequent immune response to an antigen, wherein said immune response is associated with or causes asthma comprising administering an amount of an antibody or fragment thereof that binds to OX40 and reduces or inhibits OX40 signaling, expression or activity sufficient to alleviate or ameliorate the symptom.
9. A method of alleviating or ameliorating a symptom associated with a secondary or subsequent immune response to an antigen, wherein said immune response is associated with or causes asthma and is mediated at least in part by OX40 signaling, comprising administering an amount of an antibody or fragment thereof that binds to OX40 and reduces or inhibits OX40 signaling, expression or activity sufficient to alleviate or ameliorate the symptom.
10. The method of claims 8 or 9 , wherein the immune response comprises an OX40 mediated T cell response.
11. The method of claim 10 , wherein the OX40 mediated T cell response contributes to inflammation.
12. The method of claims 8 or 9 , wherein the symptom is associated with asthma.
13. The method of claims 8 or 9 , wherein the symptom is associated with allergic asthma.
14. The method of claim 13 , wherein the symptom associated with allergic asthma comprises wheezing, shortness of breath, chest tightness, cough, and sputum production, airflow restriction, airway edema or mucus production.
15. The method of claim 13 , wherein the symptom associated with allergic asthma comprises eosinophil infiltration of lung, leukocyte infiltration of lung, hyperplasia of mucus secreting epithelium, inflammatory lesion of lung, goblet cell hyperplasia, or increased Th2 cytokine production.
16. The method of claim 15 , wherein the cytokine comprises an interleukin (IL).
17. The method of claim 16 , wherein the interleukin (IL) comprises IL-4, IL-5, IL-9, IL-13 or IL-16.
18. A method of reducing or inhibiting one or more symptoms associated with a secondary or subsequent immune response to an antigen wherein said immune response is associated with or causes asthma, comprising administering an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40 signaling, expression or activity, thereby reducing or inhibiting one or more symptoms associated with a secondary or subsequent immune response.
19. The method of claim 18 , wherein said response is mediated at least in part by OX40 or OX40 ligand (OX40L).
20. A method of reducing or inhibiting one or more symptoms associated with a secondary or subsequent immune response to an antigen, wherein said immune response is associated with or causes asthma, and is mediated at east in part by OX40 mediated T cell response, comprising administering an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40 mediated T cell response, thereby reducing or inhibiting one or more symptoms associated with a secondary or subsequent immune response associated with or that causes asthma.
21. The method of claim 20 , wherein the antibody or fragment thereof is administered to a mammalian subject.
22. The method of claim 21 , wherein the mammalian subject is a human.
23. A method of reducing or inhibiting one or more symptoms of asthma, comprising administering to a subject having or suspected of having asthma an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40 signaling, expression or activity, thereby reducing or inhibiting one or more symptoms of asthma.
24. A method of reducing or inhibiting one or more symptoms of asthma, comprising administering to a subject having or suspected of having asthma an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40 mediated T cell response, thereby reducing or inhibiting one or more symptoms of asthma.
25. A method of treating asthma, comprising administering to a subject having asthma an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40 signaling, expression or activity, thereby treating asthma.
26. A method of treating asthma, comprising administering to a subject having asthma an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40 mediated T cell response, thereby treating asthma.
27. The method of any of claims 23 to 26 , wherein the agent is administered via inhalation.
28. The method of any of claims 23 to 26 , wherein the agent is formulated into an aerosol.
29. A method of alleviating or ameliorating a symptom associated with asthma caused at least in part by exposure to an antigen, comprising administering to a subject having asthma an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40, expression or activity, thereby alleviating or ameliorating a symptom associated with asthma.
30. A method of inhibiting or reducing a recall response associated with asthma caused at least in part by exposure to an antigen, comprising administering to a subject having asthma an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40 signaling, expression or activity, thereby inhibiting or reducing a recall response associated with asthma.
31. A method of reducing or inhibiting asthma in a subject having asthma caused at least in part by exposure to an antigen, comprising administering to the subject an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40 signaling, expression or activity, thereby reducing or inhibiting asthma.
32. A method of decreasing inflammation associated with asthma, comprising administering to a subject having inflammation associated with asthma an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40 signaling, expression or activity, thereby decreasing inflammation associated with asthma.
33. The method of claim 32 , wherein the inflammation is reduced or inhibited.
34. A method of decreasing a T cell inflammatory memory response associated with asthma, comprising administering to a subject having inflammation associated with a memory response an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40 signaling, expression or activity, thereby decreasing a T cell inflammatory memory response associated with asthma.
35. The method of claim 34 , wherein the T cell inflammatory memory response is reduced or inhibited.
36. A method of reducing or inhibiting a recall immune response associated with asthma, comprising administering an amount of an antibody or fragment thereof that binds to OX40 and reduces or inhibits OX40 expression sufficient to reduce or inhibit a recall immune response associated with asthma.
37. A method of alleviating or ameliorating a symptom associated with asthma, comprising administering an amount of an antibody or fragment thereof that binds to OX40 and reduces or inhibits OX40 expression sufficient to alleviate or ameliorate the symptom associated with asthma.
38. A method of reducing or inhibiting one or more symptoms associated with asthma, comprising administering an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40 expression thereby reducing or inhibiting one or more symptoms associated with asthma.
39. A method of reducing or inhibiting one or more symptoms of asthma, comprising administering to a subject having or suspected of having asthma an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40 expression thereby reducing or inhibiting one or more symptoms of asthma.
40. A method of treating asthma, comprising administering to a subject having asthma an amount of an antibody or fragment thereof that binds to OX40 sufficient to reduce or inhibit OX40 expression thereby treating asthma.